Lyell Immunopharma, Inc. is a late-stage clinical cell therapy company focused on developing T cell therapies for cancer. Its lead product candidates include rondecabtagene autoleucel (ronde-cel, LYL314) and LYL273 (formerly GCC19CART). The company conducts its own manufacturing at its LyFE Manufacturing Center in Bothell, Washington, and has no approved products or product revenue to date.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001628280-26-017253 | EDGAR | 94K words |
| 2025-03-11 | 2024-12-31 | 0001628280-25-011978 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001628280-24-007592 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001628280-23-005572 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001628280-22-007708 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001628280-25-051619 | EDGAR | 62K words |
| 2025-08-12 | 2025-06-30 | 0001806952-25-000008 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001628280-25-025135 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-046285 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001628280-24-035617 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001628280-24-020467 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001628280-23-037360 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001628280-23-028215 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015765 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001628280-22-028929 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021109 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001628280-22-013611 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001628280-26-017244 | EDGAR | 4K words |
| 2026-03-09 | 0001193125-26-097615 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310469 | EDGAR | — |
| 2025-12-05 | 0001193125-25-309621 | EDGAR | — |
| 2025-11-12 | 0001628280-25-051603 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273269 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261753 | EDGAR | — |
| 2025-09-16 | 0001193125-25-205020 | EDGAR | — |
| 2025-08-12 | 0001806952-25-000007 | EDGAR | — |
| 2025-07-25 | 0001193125-25-164853 | EDGAR | — |
89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001806952 |
| Ticker | LYEL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Bothell, Washington |
| Website | https://www.lyell.com |
| Listed | 2021-06-17 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report